HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1

Fara Brasó-Maristany; Gaia Griguolo; Nuria Chic; Tomás Pascual; Laia Paré; Julia Maues; Patricia Galván; Maria Vittoria Dieci; Federica Miglietta; Tommaso Giarratano; Olga Martínez-Sáez; Mercedes Marín-Aguilera; Francesco Schettini; Benedetta Conte; Laura Angelats; Maria Vidal; Barbara Adamo; Montserrat Muñoz; Esther Sanfeliu; Blanca González; Ana Vivancos; Patricia Villagrasa; Joel S. Parker; Charles M. Perou; Pier Franco Conte; Aleix Prat; Valentina Guarneri

doi:10.1093/jnci/djac227

HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1

Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, Tomás Pascual, Laia Paré, Julia Maues, Patricia Galván, Maria Vittoria Dieci, Federica Miglietta, Tommaso Giarratano, Olga Martínez-Sáez, Mercedes Marín-Aguilera, Francesco Schettini, Benedetta Conte, Laura Angelats, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Esther Sanfeliu, Blanca GonzálezAna Vivancos, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, Pier Franco Conte, Aleix Prat, Valentina Guarneri

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with trastuzumab emtansine (T-DM1). However, trastuzumab deruxtecan can have considerable toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if preestablished levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29%, and 56%, respectively (P<.001). ERBB2 mRNA was statistically significantly associated with better progression-free survival (P=.002) and overall survival (OS; P=.02). These findings were independent of HER2 immunohistochemistry (IHC) levels, hormone receptor, age, brain metastasis, and line of therapy. The HER2DX risk score (P=.04) and immunoglobulin signature (P=.04) were statistically significantly associated with overall survival since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ breast cancer.

Lingua originale	Inglese
pagine (da-a)	332-336
Numero di pagine	5
Rivista	Journal of the National Cancer Institute
Volume	115
Numero di pubblicazione	3
DOI	https://doi.org/10.1093/jnci/djac227
Stato di pubblicazione	Pubblicato - 1 mar 2023
Pubblicato esternamente	Sì

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1093/jnci/djac227

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Brasó-Maristany, F., Griguolo, G., Chic, N., Pascual, T., Paré, L., Maues, J., Galván, P., Dieci, M. V., Miglietta, F., Giarratano, T., Martínez-Sáez, O., Marín-Aguilera, M., Schettini, F., Conte, B., Angelats, L., Vidal, M., Adamo, B., Muñoz, M., Sanfeliu, E., ... Guarneri, V. (2023). HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. Journal of the National Cancer Institute, 115(3), 332-336. https://doi.org/10.1093/jnci/djac227

@article{557f61e9bb934523ac9cea5a0ab66f8e,

title = "HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1",

abstract = "In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with trastuzumab emtansine (T-DM1). However, trastuzumab deruxtecan can have considerable toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if preestablished levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29%, and 56%, respectively (P<.001). ERBB2 mRNA was statistically significantly associated with better progression-free survival (P=.002) and overall survival (OS; P=.02). These findings were independent of HER2 immunohistochemistry (IHC) levels, hormone receptor, age, brain metastasis, and line of therapy. The HER2DX risk score (P=.04) and immunoglobulin signature (P=.04) were statistically significantly associated with overall survival since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ breast cancer.",

author = "Fara Bras{\'o}-Maristany and Gaia Griguolo and Nuria Chic and Tom{\'a}s Pascual and Laia Par{\'e} and Julia Maues and Patricia Galv{\'a}n and Dieci, {Maria Vittoria} and Federica Miglietta and Tommaso Giarratano and Olga Mart{\'i}nez-S{\'a}ez and Mercedes Mar{\'i}n-Aguilera and Francesco Schettini and Benedetta Conte and Laura Angelats and Maria Vidal and Barbara Adamo and Montserrat Mu{\~n}oz and Esther Sanfeliu and Blanca Gonz{\'a}lez and Ana Vivancos and Patricia Villagrasa and Parker, {Joel S.} and Perou, {Charles M.} and Conte, {Pier Franco} and Aleix Prat and Valentina Guarneri",

year = "2023",

month = mar,

day = "1",

doi = "10.1093/jnci/djac227",

language = "English",

volume = "115",

pages = "332--336",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "3",

}

Brasó-Maristany, F, Griguolo, G, Chic, N, Pascual, T, Paré, L, Maues, J, Galván, P, Dieci, MV, Miglietta, F, Giarratano, T, Martínez-Sáez, O, Marín-Aguilera, M, Schettini, F, Conte, B, Angelats, L, Vidal, M, Adamo, B, Muñoz, M, Sanfeliu, E, González, B, Vivancos, A, Villagrasa, P, Parker, JS, Perou, CM, Conte, PF, Prat, A & Guarneri, V 2023, 'HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1', Journal of the National Cancer Institute, vol. 115, n. 3, pagg. 332-336. https://doi.org/10.1093/jnci/djac227

TY - JOUR

T1 - HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1

AU - Brasó-Maristany, Fara

AU - Griguolo, Gaia

AU - Chic, Nuria

AU - Pascual, Tomás

AU - Paré, Laia

AU - Maues, Julia

AU - Galván, Patricia

AU - Dieci, Maria Vittoria

AU - Miglietta, Federica

AU - Giarratano, Tommaso

AU - Martínez-Sáez, Olga

AU - Marín-Aguilera, Mercedes

AU - Schettini, Francesco

AU - Conte, Benedetta

AU - Angelats, Laura

AU - Vidal, Maria

AU - Adamo, Barbara

AU - Muñoz, Montserrat

AU - Sanfeliu, Esther

AU - González, Blanca

AU - Vivancos, Ana

AU - Villagrasa, Patricia

AU - Parker, Joel S.

AU - Perou, Charles M.

AU - Conte, Pier Franco

AU - Prat, Aleix

AU - Guarneri, Valentina

PY - 2023/3/1

Y1 - 2023/3/1

N2 - In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with trastuzumab emtansine (T-DM1). However, trastuzumab deruxtecan can have considerable toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if preestablished levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29%, and 56%, respectively (P<.001). ERBB2 mRNA was statistically significantly associated with better progression-free survival (P=.002) and overall survival (OS; P=.02). These findings were independent of HER2 immunohistochemistry (IHC) levels, hormone receptor, age, brain metastasis, and line of therapy. The HER2DX risk score (P=.04) and immunoglobulin signature (P=.04) were statistically significantly associated with overall survival since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ breast cancer.

AB - In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with trastuzumab emtansine (T-DM1). However, trastuzumab deruxtecan can have considerable toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if preestablished levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29%, and 56%, respectively (P<.001). ERBB2 mRNA was statistically significantly associated with better progression-free survival (P=.002) and overall survival (OS; P=.02). These findings were independent of HER2 immunohistochemistry (IHC) levels, hormone receptor, age, brain metastasis, and line of therapy. The HER2DX risk score (P=.04) and immunoglobulin signature (P=.04) were statistically significantly associated with overall survival since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85166363598&partnerID=8YFLogxK

U2 - 10.1093/jnci/djac227

DO - 10.1093/jnci/djac227

M3 - Article

SN - 0027-8874

VL - 115

SP - 332

EP - 336

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 3

ER -

HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo